Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Merck's Second-To-Market Renflexis Biosimilar Priced Below The First

Jul 24 2017

• By Jessica Merrill

Competitive edge and business advantage concept as a group of hot air balloons racing to the top but an individualleader with a small balloon attached giving the winning competitor an extra boost.

Related Content

Merck Announces Major FOB Initiative With Its New Business Unit

Dec 09 2008

Samsung’s Renflexis: Second US Biosimilar To Janssen’s Remicade, With A Few Firsts

Apr 22 2017

Biosimilar Launches Depend Mostly On Patents After Supreme Court Ruling

Jun 14 2017

Merck Partners With Korea’s Samsung Bioepis On Multiple Biosimilar Targets

Feb 20 2013

Pfizer Will Support Inflectra Launch With Dedicated Sales Force

Nov 14 2016

Remicade: Biosimilars And Pricing Pressure Wear On J&J's Blockbuster Brand

Jul 18 2017

Related Companies

Merck & Co., Inc.

Johnson & Johnson

Pfizer Inc.

Samsung Bioepis Co., Ltd.

Additional Topics

Biosimilars Launches Pricing Strategies Commercial BioPharmaceutical

More from New Products

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window